PATENT CLAIM ANALYSIS

Application Number: 16119027
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["424", "400000"]

Abstract:
Provided are methods relating to compositions that include a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

Claim (Index 14):
The method of  claim 1 , wherein the method comprises:\n providing an initial administration of said CDP-camptothecin conjugate, particle or composition to said subject at a dosage of 12 mg/m 2  or 15 mg/m 2  (wherein said dosage is expressed in mg of drug, as opposed to mg of conjugate), providing one or more subsequent administrations of said CDP-camptothecin conjugate, particle or composition at a dosage of 12 mg/m 2  or 15 mg/m 2 , wherein each subsequent administration is provided, independently, between 14 days, after the previous administration, providing multiple radiation treatments, wherein an initial radiation treatment is administered with the administration of said CDP-camptothecin conjugate, particle or composition and said radiation treatments are administered daily five days a week on weekdays for at least 25 to 35 days, and administering multiple doses of capecitabine at a dosage of 825 mg/m 2  for five days on weekdays, to thereby treat the rectal cancer.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 96.0
- Lexical Diversity: 1.05556
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15312139', '14885174', '14955469', '15069208', '15723981']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6924968784554553
- 35 USC 102 Novelty (BERT): 0.4996822880653844
- Combined Prediction Score: 0.6732154194164481
- Mean Citation Score: 200.970564
- Max Citation Score: 204.61128
- Similarity Product: 131.55823696341992

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test